

## Generation of a Bartter syndrome type 3 patient-derived induced pluripotent stem cell line ISRM-BS3-UM18-iPSC (HHUUKDi014-A)

Chantelle Thimm, Chutong Zhong, Wasco Wruck, Alessandra Grillo, Rosanne Mack, Martina Bohndorf, Nina Graffmann, Anson Tang, Viola D'Ambrosio, Elizabeth R Wan, Keith Siew, Rhys D Evans, Stephan B. Walsh, James Adjaye

Article - Version of Record



### Suggested Citation:

Thimm, C., Zhong, C., Wruck, W., Grillo, A., Mack, R., Bohndorf, M., Graffmann, N., Tang, A., D'Ambrosio, V., Wan, E. R., Siew, K., Evans, R. D., Walsh, S. B., & Adjaye, J. (2025). Generation of a Bartter syndrome type 3 patient-derived induced pluripotent stem cell line ISRM-BS3-UM18-iPSC (HHUUKDi014-A). *Stem Cell Research*, 87, Article 103760. <https://doi.org/10.1016/j.scr.2025.103760>

Wissen, wo das Wissen ist.



UNIVERSITÄTS- UND  
LANDESBIBLIOTHEK  
DÜSSELDORF

This version is available at:

URN: <https://nbn-resolving.org/urn:nbn:de:hbz:061-20250716-142343-1>

Terms of Use:

This work is licensed under the Creative Commons Attribution 4.0 International License.

For more information see: <https://creativecommons.org/licenses/by/4.0>



Lab Resource: Single Cell Line

## Generation of a Bartter syndrome type 3 patient-derived induced pluripotent stem cell line ISRM-BS3-UM18-iPSC (HHUUKDi014-A)

Chantelle Thimm<sup>a</sup>, Chutong Zhong<sup>c</sup>, Wasco Wruck<sup>a</sup>, Alessandra Grillo<sup>c</sup>, Rosanne Mack<sup>a</sup>, Martina Bohndorf<sup>a</sup>, Nina Graffmann<sup>a</sup>, Anson Tang<sup>c</sup>, Viola D'Ambrosio<sup>c</sup>, Elizabeth R Wan<sup>c</sup>, Keith Siew<sup>c</sup>, Rhys D Evans<sup>c</sup>, Stephan B. Walsh<sup>c,†</sup>, James Adjaye<sup>a,b,\*</sup>

<sup>a</sup> Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine- University Düsseldorf 40225 Düsseldorf, Germany

<sup>b</sup> EGA Institute for Women's Health, Zayed Centre for Research into Rare Diseases in Children (ZCR), University College London (UCL), 20 Guilford Street, London WC1N 1DZ, UK

<sup>c</sup> Department of Renal Medicine, University College London, Royal Free Hospital, London, UK

### ABSTRACT

SIX2-positive urine-derived renal progenitor cells (UdRPCs) were isolated from an 18-year-old Bartter syndrome type 3 (BS3) patient within a homozygous CLCNKB gene deletion. Two episomal-based plasmids expressing OCT4, SOX2, NANOG, KLF4, c-MYC and LIN28 we were able to generate an integration-free induced pluripotent stem cell line (iPSC). Pluripotency was confirmed by fluorescence-activated cell sorting analysis and immunocytochemistry for the markers-OCT4, SOX2, NANOG, TRA-1-60, TRA-1-81 and SSEA4. Embryoid body-based differentiation into the three germ layers was the conducted and confirmed by immunocytochemistry. Pluritest analysis revealed a Pearson correlation of 0,93. Short tandem repeat DNA fingerprinting and karyotype analyses were performed.

Unique stem cell line identifier	<b>HHUUKDi014-A</b> <a href="https://hpscreg.eu/cell-line/HHUUKDi014-A">https://hpscreg.eu/cell-line/HHUUKDi014-A</a>	(continued)	
Alternative name(s) of stem cell line	ISRM-BS3-UM18-iPSC	Unique stem cell line identifier	<b>HHUUKDi014-A</b> <a href="https://hpscreg.eu/cell-line/HHUUKDi014-A">https://hpscreg.eu/cell-line/HHUUKDi014-A</a>
Institution	Institute for Stem Cell Research and Regenerative Medicine	Evidence of the reprogramming transgene loss (including genomic copy if applicable)	PCR
Contact information of distributor	James Adjaye, James.Adjaye@med.uni-duesseldorf.de	Associated disease	Bartter Syndrome type 3
Type of cell line	iPSC	Gene/locus	Homozygous gene deletion of CLCNKB
Origin	Human	Date archived/stock date	30.01.2024
Additional origin info required for human ESC or iPSC	Age: 18 Sex: male Ethnicity if known: any other ethnic group	Cell line repository/bank	
Cell Source	SIX2-positive urine derived renal progenitor cells (UdRPCs)	Ethical approval	The study was approved under the ethical approval "Identification of genes involved in renal, electrolyte, and urinary tract disorders" (REC reference 05/Q0508/6). The ethic approval was provided by the ethical committee of university College London.
Clonality	Clonal		The study was also approved under the ethical approval "Isolation, characterization and reprogramming of urine-derived stem cells" (Study number: 2017-2457_3. The ethic approval was provided by the ethical committee of the
Method of reprogramming	Episomal expression of OCT4, SOX2, NANOG, LIN28, c-MYC, KLF-4		(continued on next page)
Genetic Modification	YES		
Type of Genetic Modification	Hereditary.		

(continued on next column)

\* Corresponding author at: Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich-Heine- University Düsseldorf, 40225 Düsseldorf, Germany.

E-mail address: [james.adjaye@med.uni-duesseldorf.de](mailto:james.adjaye@med.uni-duesseldorf.de) (J. Adjaye).

† Deceased (RIP).

<https://doi.org/10.1016/j.scr.2025.103760>

Received 16 May 2025; Received in revised form 25 June 2025; Accepted 27 June 2025

Available online 28 June 2025

1873-5061/© 2025 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

(continued)

Unique stem cell line identifier	HHUUKDi014-A <a href="https://hpscreg.eu/cell-line/HHUUKDi014-A">https://hpscreg.eu/cell-line/HHUUKDi014-A</a>
	medical faculty of the Heinrich-Heine university Düsseldorf. All patients provided written informed consent.

1. Resource utility

The kidneys of Bartter syndrome (BS) patients excrete excessive electrolytes such as potassium, sodium and chloride due to a congenital defect in the tubules. BS is a rare polygenic disease caused by homozygous or mixed heterozygous mutations in one of the genes: SLC12A1, KCNJ1, CLCNKB, BSND or CASR (Fulchiero and Seo-Mayer, 2019; Thimm and Adjaye, 2024). This iPSC line can be used for studying the etiology of Bartter syndrome at the cellular and molecular level. Table 1

Table 1  
Characterization and validation.

Classification	Test	Result	Data
Morphology	Photography Bright field	Normal	Fig. 1 panel A
Phenotype	Immunocytochemistry	Expression of pluripotency markers: OCT4, NANOG, SOX2, Tra 1–60, SSEA-4, Tra-1–81.	Fig. 1 panel D
	Flow cytometry	1. Assess 98.3 % of OCT4 positive cells 2. Assess 99.6 % of SSEA-4 positive cells	Fig. 1 panel E
Genotype	Karyotype (G-banding) and resolution	BS3-UM18-iPSC, 46XX Resolution 450–500	panel I
Identity	Microsatellite PCR (mPCR) OR STR analysis	Not performed	N/A
		STR analysis by PCR of nine loci, matched.	Supplementary file 2
Mutation analysis (IF APPLICABLE)	PCR with Sanger Sequencing	CLCNKB mutation was found, position: 16049-17081nt.	Fig. 1 panel G
	Southern Blot OR WGS	Not performed	N/A
Microbiology and virology	Mycoplasma	Mycoplasma testing by RT-PCR	Supplementary Fig. 1B
Differentiation potential	Embryoid body formation	Expression of germ layer specific proteins:	Fig. 1 panel F
		Mesoderm – $\alpha$ -smooth muscle actin ( $\alpha$ -SMA), BRACHYURY	
		Ectoderm – PAX6, $\beta$ III-TUBULIN	
		Endoderm – SOX17, AFP	
Donor screening (OPTIONAL)	HIV 1 + 2 Hepatitis B, Hepatitis C	Not performed	N/A
Genotype additional info (OPTIONAL)	Blood group genotyping	Not performed	N/A
	HLA tissue typing	Not performed	N/A

displays the results of the characterization and validation.

2. Resource details

In 1962, Bartter et al. identified a new syndrome and named it Bartter syndrome (BS). BS is one of the rare hereditary renal tubular disorders caused by impaired salt reabsorption in the thick ascending limb (TAL) of the loop of Henle. It is associated with several electrolyte abnormalities including low potassium and chloride, salt wasting, hypokalemia, and metabolic alkalosis with hyperaldosteronism with normal blood pressure and hyperplasia of the juxtaglomerular apparatus (JGA) (Bartter et al., 1962; Lee et al., 2012; da Silva and Pfefermann, 2018; Bokhari et al., 2023). BS is a polygenic disease caused by homozygous or mixed heterozygous mutations in one of the following genes: SLC12A1, KCNJ1, CLCNKB, BSND, or CASR (Fulchiero and Seo-Mayer, 2019; Thimm and Adjaye, 2024). We generated an iPSC line from a male Bartter syndrome type 3 patient (ISRM-BS3-UM18-iPSC). SIX2-positive urine-derived renal progenitor cells (UdRPCs) were first isolated from the patient and used to generate the described iPSC line. Reprogramming was carried out by nucleofection of the episomal plasmids pEP4EO2SCK2MEN2L and pEP4EO2SET2K (7F1) expressing OCT4, SOX2, NANOG, LIN28, c-MYC and KLF-4 (Supplementary Fig. 1A). The T-13PC3 (ATCC) program and epithelial cells nucleofection kit were used. The resulting iPSC line has the typical iPSC morphology (Fig. 1A). The renal progenitor origin of UdRPC-BS3-UM18 were confirmed by immunocytochemistry for the renal stem cell marker SIX2 (Fig. 1B). The absence of exogenous OCT4 is shown in Fig. 1C. Pluripotency was confirmed by immunocytochemistry for the pluripotency-regulating transcription factors OCT4, NANOG, SOX2 and cell surface markers SSEA-4, TRA-1–60 and TRA-1–81 (Fig. 1D). Flow cytometry-based detection and quantification of OCT4 and SSEA4 expressing cells was confirmed (Fig. 1E). Pluripotency was also shown in vitro by embryoid body (EB)-based differentiation into the cell types of the three germ layers- endoderm (SOX17, AFP), ectoderm (PAX6,  $\beta$ III-TUBULIN) and mesoderm ( $\alpha$ -SMA –smooth muscle actin, BRACHYURY) (Fig. 1F). The deletion was confirmed by RT-PCR (Fig. 1G). Comparative transcriptome and cluster analysis of the ISRM-BS3-UM18-iPSC and the human embryonic stem cell line H9 revealed a Pearson correlation of 0,93. (Fig. 1H). Chromosomal content analysis counting 24 mitoses revealed a normal karyotype: ISRM-BS3-UM18-iPSC – 46, XY [22] (Fig. 1I). DNA fingerprinting confirmed the identity of ISRM-BS3-UM18-iPSC with the respective parental UdRPC (Supplementary file 2). A PCR-based Mycoplasma contamination test was negative (Supplementary Fig. 1B).

3. Materials and methods

3.1. Cell culture

UdRPCs (BS3-UM18) were isolated from urine samples and expanded as previously described (Bohndorf et al., 2017; Rahman et al., 2020). Cells were cultured on plastic plates in proliferation medium (PM) composed of 50 % DMEM high Glucose (Gibco®, life technologies, California) and 50 % Keratinocyte growth basal medium (Lonza, Basel, Switzerland) supplemented with 5 ng/ml bFGF. The DMEM high Glucose medium is supplemented with 10 % fetal bovine serum (Gibco®), 0.1 % Non-Essential Amino Acid (Gibco®), 0.5 % Glutamax (Gibco®) and 1 % Penicillin and Streptomycin (Gibco®). Cells were cultured at 37 °C, 5 % CO<sub>2</sub> and 5 % O<sub>2</sub>. ISRM-BS3-UM18 was cultured in StemMACS iPS-Brew XF Medium (Miltenyi Biotec, Bergisch Gladbach, Germany) with 1 % Penstrep on Matrigel at 37 °C and 5 % CO<sub>2</sub>. Cells were split at a 1:6 ratio into new matrigel coated plates. The characterization of the cells was carried out at passage 19.

### 3.2. Derivation of iPSCs

SIX2-positive BS3-UM18 UdrPC were reprogrammed into iPSCs (Bohndorf et al., 2017; Yu et al., 2011; Ncube et al., 2023) using the Amaxa nucleofector (Lonza, Basel, Switzerland) program T-13PC3 (ATCC). The epithelial cells nucleofection kit from LONZA was used for nucleofecting approximately 3 µg each of the two plasmids pEP4EO2SCK2MEN2L and pEP4EO2SET2K (Supplementary Fig. 1A). In addition, 0.5 µM A83-01, 0.5 µM PD0325901, 10 µM Y-27632, and 3 µM CHIR99021 were supplemented to inhibit TGFβ-, MEK-, and Rock-signalling and activate WNT-signalling pathway. Cells were cultured for 24 h in Proliferation medium supplemented with 10 µM Y-27632 on Matrigel® at 37 °C and 5 % CO<sub>2</sub>. After 24 h the Medium was changed to StemMACS iPS-Brew XF Medium (Miltenyi Biotec, Bergisch Gladbach, Germany) with daily medium changes. Well-defined iPSC colonies were picked and detached using PBS lacking Mg<sup>2+</sup> and Ca<sup>2+</sup> and distributed at a 1:6 ratio into new matrigel coated plates.

### 3.3. PCR

Supernatants from dense cultures were collected, and PCR was run to confirm the absence of mycoplasma contamination. To confirm the vector dilution, genomic DNA was extracted using the DNeasy Blood and Tissue kit (QIAGEN, Hilden, Germany). PCR was carried out using the GoTaq DNA Polymerase kit (Promega) with exogenous OCT4 primers (Table 1).

### 3.4. DNA fingerprint analysis

STR analysis was performed using genomic DNA extracted using the DNeasy Blood and Tissue kit (QIAGEN, Hilden, Germany). By using the GoTaq DNA Polymerase kit (Promega), the STR analysis was performed by PCR using the following primers: D16S539, D13S317 and D7S820. RPL0 served as a housekeeping gene for normalization. The PCR program is as followed:

Cycle 1 (x1): 94 °C for 3 min  
 Cycle 2 (x10): 94 °C for 30 s, 60 °C for 15 s, 70 °C for 45 s  
 Cycle 3 (x20): 94 °C for 30 s, 60 °C for 15 s, 70 °C for 45 s  
 Cycle 4 (x1): 60 °C for 30 min  
 Cycle 5: 4 °C end

Primary BS3-UM18 UdrPC cells was used for comparison-H<sub>2</sub>O served as a negative control. The PCR amplicons were resolved by gel electrophoresis using 2.5 % agarose. Primer sequences are shown in Table 1.

### 3.5. Embryoid body (EB) formation

Embryoid bodies are three-dimensional aggregates that confirm the pluripotent properties of iPSCs. Based on this, EBs were also produced from the cultured iPSCs. First, the iPSCs were cultured on Matrigel-coated plates until they were subconfluent. Then a 6 mm Petri dish (greiner BIO-ONE, Kremsmünster, Austria) was coated with an anti-adherence rinsing solution (Stemcell technologies) for 10 min at 37 °C. The subconfluent wells were transferred 1:1 into a coated Petri dish. The Petri dish was cultivated for 24 h in a low oxygen incubator. As usual, the cells were cultivated in StemMACS iPS-Brew XF medium with 10 µM Y-27632. After 24 h, the cells were transferred to a normoxic incubator on a shaking platform. After approximately three days, the medium was changed to high-glucose DMEM, containing 1 % NEAA, to generate the EBs. After 7 days, the EBs are transferred to a 24-well plate coated with Matrigel and cultured till confluent.

### 3.6. Immunofluorescence

Cells were fixed with 4 % paraformaldehyde for 15 min at room temperature (RT). Cells were washed three times with PBS. Afterwards an incubation with 0.05 % Tween-20/PBS for 10 min. The cells were treated three times with PBS and continued blocking the cells with 3 % BSA/PBS. Thereafter they were incubated with the respective primary antibodies (Table 2) overnight at 4 °C. Followed by one washing step with Triton x-100/PBS and two washing steps with PBS. The cells were incubated for 2 h with Alexa488 or Alexa555-conjugated secondary antibodies and nuclear Hoechst at RT. Fluorescence images were captured by a LSM700 microscope (Carl Zeiss).

### 3.7. Flow-cytometry and immunofluorescence-based detection of pluripotency-associated proteins

Cells cultured in 6-well plates were washed twice with PBS. Afterwards they were replaced with 500 µl Triple-E (Gibco®, life technologies, California) for 10 min at 37 °C and 5 % CO<sub>2</sub> in the incubator. The reaction is stopped by 1 ml StemMACS iPS-Brew XF Medium (MiltenyiBiotec, Bergisch Gladbach, Germany). Cells from each 6-well was transferred into FACS-Tubes (Falcon, New York, USA) and centrifuged by 190 g, 5 min. Afterwards the cells were fixed with 4 % paraformaldehyde (polysciences, Illinois, USA) for 15 min at RT. Followed by three washings steps with PBS at 500 g 5 min. Blocking was carried out with 1 – 2 ml 3 % BSA (Sigma-Aldrich, St.Louis, USA) for 1 h at RT. The cells were separated with a 0.4 µm meshstainer (greiner BIO-ONE, Kremsmünster, Austria). Followed by a centrifugation step at 300 g, 10 min, RT. Cell pellet were resuspended with 98 µl FACS Buffer consisting of 50 ml PBS (–/–), 0.5 % BSA, 2 mM EDTA, which can be stored by 2–8 °C. 2 µl of antibody were added. Incubation was overnight at 4 °C. Cells were washed three times with PBS and diluted in 100 µl FACS Buffer, 0.2 ul of second antibody (Table 2) for 1 h at the shaking plate in the dark, RT. After three washing steps the cell pellet were resuspend in 200–300 µl FACS Buffer and stored at 4 °C.

### 3.8. Karyotype analysis

Karyotype analysis was performed and evaluated at the Institute of Human Genetics and Anthropology, Heinrich-Heine-University, Düsseldorf.

### 3.9. NGS analysis

For the NGS experiments, 50 ng RNA preparations were sequenced via 3'RNA-Seq on a Illumina NextSeq 2000 at the core facility Biomedizinisches Forschungszentrum (BMFZ)- Heinrich Heine University Düsseldorf. The reads from the resulting fastq files were aligned against the GRCh38 genome via the HISAT2 (version 2.1.0) software (Kim et al., 2015) and summarized per gene with the subread (1.6.1) featurecounts software (Liao et al., 2014) using the ENSEMBL annotation file Homo\_sapiens.GRCh38.109.gtf as described in our previous publication (Martins et al., 2020). The summarized RNA-Seq counts were corrected for batch effects and normalized within the R/Bioconductor (Gentleman et al., 2004) environment using the batch effect removal and voom normalization from the package limma (Smyth, 2004). Dendrograms and correlations were calculated using Pearson correlation as a similarity measure.

### 3.10. Genotyping

Genotyping was performed by multiplex polymerase chain reaction and next generation sequencing of patient genomic DNA for a panel of genes associated with inherited tubular disease (inclusive of CLCNKB). The panel (R198) of genes associated with tubular disease currently tested can be found at <https://panelapp.genomicsengland.co.uk/pan>

Table 2  
Reagents details.

	Antibodies used for immunocytochemistry/flow-cytometry			
	Antibody	Dilution	Company Cat #	RRID
Characterization	Mouse-SIX2	1:200	Abnova #H0010756-M01	AB_489974
Flow Cytometry	Rabbit anti-OCT4	1:50	Cell Signaling Technologies #2840S	AB_2167691
Flow Cytometry	Mouse anti-SSEA4	1:50	Cell Signaling #MC813	AB_4755
Pluripotency Marker	Rabbit anti-OCT4	1:200	Cell Signaling Technologies #2840S	AB_2167691
Pluripotency Marker	Rabbit anti-SOX2	1:200	Cell Signaling Technologies #3579S	AB_2195767
Pluripotency Marker	Rabbit anti-NANOG	1:200	Cell Signaling Technologies #4903S	AB_10559205
Pluripotency Marker	Mouse anti-Tra-1-60	1:200	Cell Signaling Technologies #4746S	AB_2119059
Pluripotency Marker	Mouse anti-Tra-1-81	1:200	Cell Signaling Technologies #4745S	AB_2119060
Pluripotency Marker	Mouse anti-SSEA4	1:200	Cell Signaling #MC813	AB_4755
e.g. Differentiation Markers	Rabbit anti-PAX6	1:200	Cell Signaling #D3A9V	AB_60433
	Mouse anti-aSMA	1:1000	Dako # M0851	AB_2223500
	Mouse anti-IgG-SOX17	1:50	R&D System #AF1924	AB_355060
	Rabbit anti-BIII Tubulin	1:1000	SySy # 302,304	AB_10805138
	Rabbit anti-AFP	1:200	Cell Signaling Technology # 2137S	AB_2209744
	Rabbit anti-brachyury	1:200	Abcam #ab209665	AB_270925
Secondary antibodies Flow Cytometry	anti-rabbit- Alexa488	1:50	Thermo Fisher Scientific # A27034	AB_2536097
Secondary antibody	anti-rabbit- Alexa488	1:500	Thermo Fisher Scientific # A27034	AB_2536097
Secondary antibody	anti-mouse- Alexa555	1:500	Thermo Fisher Scientific # A21424	AB_141780
Nuclear Co- Staining	Hoechst	1:5000	Thermo Fisher Scientific # H3569	AB_2651133
Episomal plasmid (exogenous) House-Keeping Genes Mycoplasma ITW Reagents #A3744	<b>Primers</b>			
	<b>Target</b>	<b>Size of band</b>	<b>Forward/Reverse primer (5'-3')</b>	
	OCT4	657 bp	AGTGAGAGGCAACCTGGAGA/ AGGAAGTGTCTCCTCACGA	
	RPL0	42 bp	TCGACAATGGCAGCATCTAC/ ATCCGTCTCCACAGACAAGG	
	mycoplasma-specific 16S rRNA gene	270 bp	Negative samples show a 270 bp band only	
STR analysis	D16S539		Positive ones have two bands 270 bp & 357 bp	
			GGGGGTCTAAGAGCTTGTA AAAAG	
	D13S317		GTTTGTGTGTATCTGTAAGCATGTATC	
			ACAGAAGTCTGGGATGTGGAGGA	
	D7S820		GGCAGCCCCAAAAGACAGA	
			ATGTTGGTCAGGCTGACTATG	
	vWA		GATTCCACATTTATCCTCATTGAC	
			CTAGTGGATGATAAGAAATAATCAGTATGTG	
	Th01		GGACAGATGATAAATACATAGGATGGATGG	
			ATTCAAAGGGTATCTGGGCTCTGG	
	Amelogenin		GTGGGCTGAAAAGCTCCCGATTAT	
			ACCTCATCCTGGGCACCCTGGTT	
Genotyping	D5S818		AGGCTTGAGGCCAACCATCAG	
			GGTGATTTTCTCTTTGGTATCC	
	CSF1		AGCCACAGTTTACAACATTTGTATCT	
			AACCTGAGTCTGCCAAGGACTAGC	
	TPOX		TTCCACACACCACTGGCCATCTTC	
			ACTGGCACAGAACAGGCACCTTAGG	
	CLCNKB 4	568 bp	GGAGGAACTGGGAACACACAGGT	
	Position: 15481-16028nt		GAAGATAAGGCGGGTTGGGG	
	CLCNKB 5	507 bp	CTTGGGTGAGCAGTGGGGTCC	
	Position: 16049-16537nt		AAATAGCCTTCAGTGTTCAT	
	CLCNKB 6	562 bp	TATGGGGCTATTGTGACTA	
	Position: 16537-17081nt		TAGTCACAATAGCCCCATAG	
			AGGAAGCAGCATAAGACG	

els/292/ (Hureaux et al., 2019; Ashton et al., 2018). In addition the deletion within the CLCNKB gene of the BS3-UM18 UdrPC and the derived iPSC was confirmed by PCR and Sanger sequenced at the core facility- Biomedizinisches Forschungszentrum (BMFZ)-Heinrich Heine University Düsseldorf.

3.11. Patient recruitment

Patients were recruited from the University College London Department of Renal Medicine specialist clinics for renal tubular disorders based at the Royal Free Hospital and Great Ormond Street Hospital. Patients are referred to this clinic with confirmed or possible

inherited disorders of tubular function. From our cohort, patients with genotyped Bartter's Syndrome Type 3 [OMIM: 607,364 | GENE: CLCNKB] were selected for isolation of urine-derived cells.

3.12. Ethics

The study was approved under the ethical approval "Identification of genes involved in renal, electrolyte, and urinary tract disorders" (REC reference 05/Q0508/6). The study was also approved under the ethical approval "Isolation, characterization and reprogramming of urine-derived stem cells" (Study number: 2017-2457\_3. The ethic approval was provided by the ethical committee of the medical faculty of the



Heinrich Heine university Düsseldorf.

All patients provided written informed consent

#### 4. Funding statement

J.A. acknowledges the medical faculty of Heinrich Heine University for financial support.

#### CRedit authorship contribution statement

**Chantelle Thimm:** Writing – review & editing, Writing – original draft, Visualization, Methodology, Investigation, Formal analysis. **Chutong Zhong:** Resources, Methodology, Investigation. **Wasco Wruck:** Software, Formal analysis. **Alessandra Grillo:** Resources, Methodology. **Rosanne Mack:** Methodology. **Martina Bohndorf:** Methodology. **Nina Graffmann:** Methodology. **Anson Tang:** Resources. **Viola D'Ambrosio:** Resources. **Elizabeth R Wan:** Resources. **Keith Siew:** Supervision, Funding acquisition, Conceptualization. **Rhys D Evans:** Resources. **Stephan B. Walsh:** Supervision, Funding acquisition, Conceptualization. **James Adjaye:** Supervision, Project administration, Funding acquisition, Conceptualization.

#### Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

#### Acknowledgements

S.B.W., A.G., E.R.W., A.T. are supported by Kidney Research UK grant [RP\_017\_20190306; TF\_007\_20191202; ST\_001\_20221128]. K.S. acknowledges this research was funded in part by the Wellcome Trust [Grant number 110282/Z/15/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2025.103760>.

#### References

- Ashton, E.J., Legrand, A., Benoit, V., Roncelin, I., Venisse, A., Zennaro, M.-C., Jeunemaitre, X., Iancu, D., Van'T Hoff, W.G., Walsh, S.B., Godefroid, N., Rothier, A., Del Favero, J., et al., 2018. Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies. *Kidney Int.* 93, 961–967.
- Bartter, F.C., Pronove, P., Gill, J.R., Maccardie, R.C., 1962. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A New Syndrome. *Am. J. Med.* 33, 811–828.
- Bohndorf, M., Ncube, A., Spitzhorn, L.-S., Enczmann, J., Wruck, W., Adjaye, J., 2017. Derivation and characterization of integration-free iPSC line ISRM-UM51 derived from SIX2-positive renal cells isolated from urine of an african male expressing the CYP2D6 \*4/\*17 variant which confers intermediate drug metabolizing activity. *Stem Cell Res.* 25, 18–21.
- Bokhari, S.R.A., Zulfiqar, H., Mansur, A., 2023. Bartter Syndrome. StatPearls Publishing LLC.
- da Silva, C.T., Pfefermann, H.I., 2018. Bartter syndrome: causes, diagnosis, and treatment. *Int. J. Nephrol. Renovasc. Dis.* 11, 291–301.
- Fulchiero, R., Seo-Mayer, P., 2019. Bartter Syndrome and Gitelman Syndrome. *Pediatr. Clin. North Am.* 66, 121–134.
- Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., et al., 2004. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol.* 5.
- Hureauux, M., Ashton, E., Dahan, K., Houillier, P., Blanchard, A., Cormier, C., Koumakis, E., Iancu, D., Belge, H., Hilbert, P., Rothier, A., Del Favero, J., Schaefer, F., et al., 2019. High-throughput sequencing contributes to the diagnosis of tubulopathies and familial hypercalcemia hypocalciuria in adults. *Kidney Int.* 96, 1408–1416.
- Kim, D., Langmead, B., Salzberg, S.L., 2015. HISAT: a fast spliced aligner with low memory requirements. *Nat. Methods* 12, 357–360.
- Lee, B.H., Cho, H.Y., Lee, H., Han, K.H., Kang, H.G., Ha, I.S., Lee, J.H., Park, Y.S., Shin, J. I., Lee, D.-Y., Kim, S.-Y., Choi, Y., Cheong, H.I., 2012. Genetic basis of Bartter syndrome in Korea. *Ndt* 27, 1516–1521.
- Liao, Y., Smyth, G.K., Shi, W., 2014. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30, 923–930.
- Martins, S., Müller-Schiffmann, A., Erichsen, L., Bohndorf, M., Wruck, W., Slegers, K., Van Broeckhoven, C., Korth, C., Adjaye, J., 2020. iPSC-Derived Neuronal Cultures Carrying the Alzheimer's Disease Associated TREM2 R47H Variant Enables the Construction of an Aβ-Induced Gene Regulatory Network. *Int. J. Mol. Sci.* 21, 4516.
- Ncube, A., Bewersdorf, L., Spitzhorn, L.-S., Loerch, C., Bohndorf, M., Graffmann, N., May, L., Amzou, S., Fromme, M., Wruck, W., Strnad, P., Adjaye, J., 2023. Generation of two Alpha-1 antitrypsin deficiency patient-derived induced pluripotent stem cell lines ISRM-AATD-iPSC-1 (HHUUKDi011-a) and ISRM-AATD-iPSC-2 (HHUUKDi012-a). *Stem Cell Res.* 71, 103171.
- Rahman, M.S., Wruck, W., Spitzhorn, L.-S., Nguyen, L., Bohndorf, M., Martins, S., Asar, F., Ncube, A., Erichsen, L., Graffmann, N., Adjaye, J., 2020. The FGF, TGFβ and WNT axis Modulate Self-renewal of Human SIX2 + Urine Derived Renal Progenitor Cells. *Sci. Rep.* 10, 739.
- Smyth, G.K., 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* 3, 1–25.
- Thimm, C., Adjaye, J., 2024. Untangling the Uncertain Role of Overactivation of the Renin–Angiotensin–Aldosterone System with the Aging Process based on Sodium Wasting Human Models. *Int. J. Mol. Sci.* 25, 9332.
- Yu J, Chau KF, Vodyanik MA, Jiang J, Jiang Y. Efficient Feeder-Free Episomal Reprogramming with Small Molecules. Pera M, editor. *PLoS ONE*. 2011; 6: e17557.